Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Assets (2016 - 2026)

Myriad Genetics has reported Assets over the past 16 years, most recently at $706.6 million for Q4 2025.

  • Quarterly Assets fell 31.24% to $706.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $706.6 million through Dec 2025, down 31.24% year-over-year, with the annual reading at $706.6 million for FY2025, 31.24% down from the prior year.
  • Assets was $706.6 million for Q4 2025 at Myriad Genetics, down from $728.1 million in the prior quarter.
  • Over five years, Assets peaked at $1.4 billion in Q2 2021 and troughed at $677.3 million in Q2 2025.
  • The 5-year median for Assets is $1.2 billion (2023), against an average of $1.1 billion.
  • Year-over-year, Assets decreased 1.9% in 2023 and then plummeted 37.58% in 2025.
  • A 5-year view of Assets shows it stood at $1.3 billion in 2021, then decreased by 9.24% to $1.2 billion in 2022, then dropped by 4.35% to $1.1 billion in 2023, then dropped by 10.37% to $1.0 billion in 2024, then tumbled by 31.24% to $706.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Assets are $706.6 million (Q4 2025), $728.1 million (Q3 2025), and $677.3 million (Q2 2025).